Heartbeam Raised to Buy From Speculative Buy by Benchmark

Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Industrials, Basic Materials and Healthcare sectors led shares higher.

At the close in NYSE, the Dow Jones Industrial Average gained 1.05%, while the S&P 500 index climbed 0.68%, and the NASDAQ Composite index climbed 0.33%.

The best performers of the session on the Dow Jones Industrial Average were Nike Inc (NYSE:NKE), which rose 3.91% or 2.48 points to trade at 65.81 at the close. Meanwhile, Caterpillar Inc (NYSE:CAT) added 3.53% or 20.99 points to end at 615.35 and Johnson & Johnson (NYSE:JNJ) was up 3.29% or 6.58 points to 206.54 in late trade.

The worst performers of the session were Microsoft Corporation (NASDAQ:MSFT), which fell 2.78% or 13.70 points to trade at 478.56 at the close. Walmart Inc (NASDAQ:WMT) declined 1.66% or 1.91 points to end at 113.15 and Boeing Co (NYSE:BA) was down 0.82% or 1.65 points to 198.72.

The top performers on the S&P 500 were GE Vernova LLC (NYSE:GEV) which rose 15.59% to 722.77, Celanese Corporation (NYSE:CE) which was up 7.60% to settle at 43.26 and Western Digital Corporation (NASDAQ:WDC) which gained 7.32% to close at 181.95.

The worst performers were Uber Technologies Inc (NYSE:UBER) which was down 5.51% to 84.16 in late trade, Netflix Inc (NASDAQ:NFLX) which lost 4.15% to settle at 92.69 and HCA Holdings Inc (NYSE:HCA) which was down 4.05% to 468.73 at the close.

The top performers on the NASDAQ Composite were Beasley Broadcast Group Inc (NASDAQ:BBGI) which rose 302.17% to 16.69, Heartbeam Inc (NASDAQ:BEAT) which was up 94.29% to settle at 1.57 and Enveric Biosciences Inc (NASDAQ:ENVB) which gained 73.31% to close at 10.26.

The worst performers were Work Medical Technology Group Ltd (NASDAQ:WOK) which was down 96.59% to 0.19 in late trade, Agape ATP Corp (NASDAQ:ATPC) which lost 94.85% to settle at 0.07 and PomDoctor Ltd ADR (NASDAQ:POM) which was down 90.77% to 0.50 at the close.

Rising stocks outnumbered declining ones on the New York Stock Exchange by 1925 to 821 and 91 ended unchanged; on the Nasdaq Stock Exchange, 2119 rose and 1266 declined, while 167 ended unchanged.

Shares in GE Vernova LLC (NYSE:GEV) rose to all time highs; rising 15.59% or 97.47 to 722.77. Shares in Western Digital Corporation (NASDAQ:WDC) rose to all time highs; rising 7.32% or 12.41 to 181.95. Shares in Caterpillar Inc (NYSE:CAT) rose to all time highs; rising 3.53% or 20.99 to 615.35. Shares in Beasley Broadcast Group Inc (NASDAQ:BBGI) rose to 52-week highs; up 302.17% or 12.54 to 16.69. Shares in Work Medical Technology Group Ltd (NASDAQ:WOK) fell to all time lows; down 96.59% or 5.38 to 0.19. Shares in Agape ATP Corp (NASDAQ:ATPC) fell to all time lows; falling 94.85% or 1.25 to 0.07. Shares in PomDoctor Ltd ADR (NASDAQ:POM) fell to all time lows; losing 90.77% or 4.92 to 0.50.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 6.85% to 15.77.

Gold Futures for February delivery was up 0.49% or 20.75 to $4,256.95 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 1.17% or 0.68 to hit $58.93 a barrel, while the February Brent oil contract rose 1.11% or 0.69 to trade at $62.63 a barrel.

EUR/USD was up 0.58% to 1.17, while USD/JPY fell 0.47% to 156.04.

The US Dollar Index Futures was down 0.56% at 98.64.

Investing.com -- HeartBeam Inc (NASDAQ:BEAT) stock surged 52.6% in premarket trading Wednesday after the medical technology company announced it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment.

The clearance follows a successful appeal of a previous Not Substantially Equivalent (NSE) determination by the FDA. HeartBeam’s patented technology allows patients to obtain clinical-grade ECG readings from home using a credit card-sized device that captures heart signals in three dimensions.

Unlike single-lead or 6-lead consumer devices, HeartBeam’s technology synthesizes a complete 12-lead ECG representation, which is then reviewed by a board-certified cardiologist. This advancement enables patients to record ECG data during actual cardiac events rather than waiting to visit a doctor’s office.

"This FDA clearance is a defining moment for HeartBeam, and the true beginning of our mission to revolutionize cardiac care," said Robert Eno, Chief Executive Officer of HeartBeam.

The company plans to initiate a limited U.S. commercial launch in the first quarter of 2026, targeting select concierge and preventive cardiology practices. HeartBeam also intends to pursue a heart attack detection indication and advance development of an on-demand 12-lead ECG extended wear monitor.

Dr. Robert A. Harrington, a member of HeartBeam’s scientific advisory board, noted that the technology addresses a critical challenge in cardiology by allowing patients to collect meaningful ECG data at the exact moment symptoms occur, enabling physicians to gain clearer understanding of patients’ conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.